性结肠炎,病理生理机制和药物重用:一个新的治疗黎明叙述审查
Mostafa M Bahaa1,2, Mahmoud S Abdallah3, Esraa M Mosalam3,4
1Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt.
Inflammopharmacology
|March 2, 2026
概括
重用现有药物为性结肠炎 (UC) 患者提供了新的希望. 几种药物表现出抗炎作用,改善肠道屏障完整性,减少UC模型中的氧化应激.
科学领域:
- 胃肠病学和药理学 胃肠病学和药理学
- 炎症性肠道疾病研究研究
- 药物重用策略的策略.
背景情况:
- 性结肠炎 (UC) 是一种炎症性肠病,其全球流行率正在上升.
- 目前的小分子药物和生物药物等治疗方法对约三分之一的UC患者是无效的.
- 多种分子通路,包括IL-6/STAT3和AMPK,都与UC病理生理学有关.
研究的目的:
- 调查用于治疗性结肠炎 (UC) 的现有药物的重新用途的潜力.
- 在UC模型上评估各种药物的抗炎和保护作用.
- 探索这些重用药物的治疗益处背后的机制.
主要方法:
- 对UC的重用药物的体外,体内和临床研究的审查.
- 对肠道屏障完整性,氧化应激和炎症途径数据的分析.
- 检查诸如甲福明,阿托瓦斯塔丁和尼塔佐胺等药物的抗炎性质.
主要成果:
- 几种药物,包括罗西格利塔,甲福明和阿托瓦斯塔丁,在UC模型中表现出显著的抗炎作用.
- 这些药物对肠道屏障完整性,氧化应激和关键炎症通路产生了积极的影响.
- 在UC的细胞和临床模型中观察到积极的影响.
结论:
- 重新利用现有药物为新型UC疗法提供了一个有希望的途径.
- 了解这些药物的机制可以导致更有效的UC治疗策略.
- 对这些重用药物的进一步研究可能会改善UC患者的治疗结果.
相关概念视频
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.7K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
Inflammatory Bowel Disease II: Ulcerative Colitis
34
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
34


